T 150 (Tarceva 150 mg)
Generic Name: erlotinib
Pill imprint T 150 has been identified as Tarceva 150 mg.
Tarceva is used in the treatment of non-small cell lung cancer; pancreatic cancer; renal cell carcinoma and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Tarceva 150 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for T 150 (Tarceva 150 mg)
- Generic Name:
- 150 mg
- 10.00 mm
- Prescription only
- Drug Class:
- EGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- National Drug Code (NDC):
- Inactive Ingredients:
- lactose monohydrate
sodium starch glycolate
sodium lauryl sulfate
|NDC Code||Manufacturer / Repackager|
|54868-5447||Physicians Total Care Inc (repackager)|
|54569-5848||A S Medication Solutions LLC (repackager)|
Note: Inactive ingredients may vary.
Tarceva is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...